STOCK TITAN

Avalon GloboCare to Participate in the 35th Annual Roth Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Avalon GloboCare Corp. (NASDAQ: ALBT), a key player in cell-based technology, announced participation in the 35th Annual Roth Conference on March 13-14, 2023, held at The Ritz Carlton, Laguna Niguel in Dana Point, California. Luisa Ingargiola, Chief Financial Officer, will host one-on-one and small group meetings for investors.

The conference serves as a platform for Avalon to showcase its innovative cellular therapeutics and precision diagnostics. Investors interested in meetings can email oneononerequests@roth.com.

Positive
  • None.
Negative
  • None.

FREEHOLD, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it has been invited to participate in the 35th Annual Roth Conference being held on March 13 and 14, 2023.

Luisa Ingargiola, Chief Financial Officer of Avalon, will be available for one-on-one and small group investor meetings during those days. The Conference will be held at The Ritz Carlton, Laguna Niguel located in Dana Point, California.

To arrange a 1-on-1 please email oneononerequests@roth.com, or contact your Roth sales team. For more information about the event or questions about registration, please contact your Roth representative.

About Avalon GloboCare Corp.

Avalon GloboCare Corp. (NASDAQ: ALBT) is a clinical-stage biotechnology company dedicated to developing and delivering innovative, transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.

For the latest updates on Avalon GloboCare’s developments, please follow our twitter at @avalongc_avco

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the transaction and the business of Laboratory Services. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com

Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com

 


FAQ

What is Avalon GloboCare's participation in the Roth Conference 2023?

Avalon GloboCare Corp. (NASDAQ: ALBT) will participate in the 35th Annual Roth Conference on March 13-14, 2023.

Who will represent Avalon GloboCare at the Roth Conference?

Luisa Ingargiola, Chief Financial Officer, will represent Avalon GloboCare at the Roth Conference.

Where is the 35th Annual Roth Conference being held?

The conference is being held at The Ritz Carlton, Laguna Niguel, in Dana Point, California.

How can investors arrange meetings with Avalon GloboCare during the Roth Conference?

Investors can arrange one-on-one meetings by emailing oneononerequests@roth.com.

What are Avalon GloboCare's main business focuses?

Avalon GloboCare focuses on developing cellular therapeutics, precision diagnostics, and clinical laboratory services.

Avalon GloboCare Corp.

NASDAQ:ALBT

ALBT Rankings

ALBT Latest News

ALBT Stock Data

4.20M
684.17k
37.47%
1.53%
7.2%
Real Estate Services
Biological Products, (no Disgnostic Substances)
Link
United States of America
FREEHOLD